[24] These data strongly suggest that higher DNA-PK expression can prompt higher AMPK activity, causing higher pACC levels, and ultimately identifies ovarian cancer cells resistant to paclitaxel and sensitive to doxorubicin treatment. This evidence concerns the gene PRKDC and ovarian carcinoma.